Antibody response to respiratory syncytial virus infection in children

Susanna Esposito, Elisa Scarselli, Mara Lelii, Alessia Scala, Alessandra Vitelli, Stefania Capone, Marco Fornili, Elia Biganzoli, Annalisa Orenti, Alfredo Nicosia, Riccardo Cortese, Nicola Principi

Research output: Contribution to journalArticlepeer-review


The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitated by knowledge of the natural immune response to this virus. The aims of this study were to evaluate the neutralizing antibody response of a cohort of healthy children 6 copies/mL (p = 0.03), and those with LRTIs during the study period (p = 0.03), but it was not associated with the immune response (p = 0.41). In conclusion, natural RSV infection seems to evoke a low immune response in younger children. To be effective in this infant population, which is at highest risk of developing severe LRTIs, vaccines must be able to induce in the first months of life a stronger immune response than that produced by the natural infection.

Original languageEnglish
Pages (from-to)1700-1706
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Issue number7
Publication statusPublished - 2016


  • neutralizing antibody
  • pediatric infectious diseases
  • respiratory tract infection
  • RSV
  • RSV vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Antibody response to respiratory syncytial virus infection in children'. Together they form a unique fingerprint.

Cite this